Stock Ratings / Health Care / GNTA / financials

MGX (41) ALGS (26) ESLA (41) EVAX (58) ⌘ Pro Terminal →

Genenta Science S.p.A. (GNTA) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$0.62 +2.48% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Genenta Science S.p.A. (GNTA) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $29.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERHOLD / WATCH • C

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+1.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GNTA)Realized 20D OHLCV Swing Band: ±12.5%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • Trailing 12 Months

How GNTA Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$837.0K (0% FCF Margin)

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GNTA)

✓Walkthrough of GNTA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

GNTA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -12.68%▲ RESISTANCE BREAKOUT

2026-10-30O $0.62H $0.64L $0.60C $0.62VOL 67.2K

RES: $0.50SUP: $0.31SMA50: $0.79SMA200: $1.04

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GNTA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GNTA Butterfly Map → + Track GNTA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on GNTA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GNTA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for GNTA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GNTA)

Health Care Rank #177 of 1016 ⚔️ MGX vs GNTA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GNTA vs. MGX, ALGS, ESLA, EVAX)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Genenta Science S.p.A. (GNTA) ranks #177 by composite RQD confidence (62/100, grade C) and #804 by equity capitalization ($29.9M). Within this direct 5-issuer industry benchmark cohort, GNTA leads on earnings valuation at N/A trailing P/E, while MGX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GNTA currently leads its immediate peer cohort in composite quantitative strength at 62/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
GNTA ACTIVE Genenta Science S.p.A.	C	62/100	—	—	—	+2.48%	$29.9M	Benchmark Subject
MGX Metagenomi Therapeutics Inc.	D-	41/100	—	—	-35.0%	+1.03%	$31.4M	/mgx-vs-gnta →
ALGS Aligos Therapeutics Inc.	E	26/100	—	—	-35.0%	-2.71%	$31.4M	/algs-vs-gnta →
ESLA Estrella Immunopharma Inc.	D-	41/100	—	—	-35.0%	-11.32%	$31.7M	/esla-vs-gnta →
EVAX Evaxion A/S	D+	58/100	—	—	—	-0.96%	$27.8M	/evax-vs-gnta →

2. GNTA Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Genenta Science S.p.A. (GNTA) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $29.9M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. GNTA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GNTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Genenta Science S.p.A. (NASDAQ: GNTA) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $0.62 (+2.48% 1D, market cap $29.9M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, GNTA ranks #177 in composite RQD confidence.

How does GNTA compare to MGX and ALGS in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), GNTA carries a Roarable C (62/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MGX (Metagenomi Therapeutics Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $31.4M) and ALGS (Aligos Therapeutics Inc.) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $31.4M). Among the 5-stock peer group, GNTA leads on earnings multiple (N/A) while MGX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GNTA?

For Genenta Science S.p.A. (GNTA), key quantitative strengths include Big institutional funds and options desks are actively positioning on the bullish side. and sector rank #177 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GNTA trading relative to its 50-day, 200-day, and 52-week technical levels?

GNTA last traded at $0.62 (+2.48% on volume of 153,196 shares), positioning the stock -21.52% below its 50-day simple moving average ($0.79) and -40.38% below its 200-day simple moving average ($1.04). Across its 52-week range of $0.55 to $2.75, GNTA sits at the 3.2% percentile with a 14-day RSI of 36.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.70).